ASPHALION SERVICE “MINI PILL” | ORPHAN DRUG DESIGNATION

November 25, 2022

About 30 million people living in the European Union (EU) suffer from a rare disease. The European Medicines Agency (EMA) plays a central role in facilitating the development and authorisation of medicines for rare diseases, which are termed ‘orphan medicines‘ in the medical world.

Regarding the US, the FDA has authority to grant orphan drug designations to drugs of biological products to prevent, diagnose or treat a rare disease or condition, with an estimated population of around 30 million people suffering from a rare disease in the country.

Check out our #serviceminipill to see how ASPHALION can help you with the whole ODD application process!!

For further information, please contact us at: info@asphalion.com

 

Search News & Events

  • Filter by category

Share

Related news and events

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting